Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026.

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix and previously served as chief operating and commercial officer at Chimerix, where he directed corporate strategy and led the transaction that sold Chimerix to Jazz. He helped navigate the regulatory process for U.S. approval and launch of Modeyso (dordaviprone), the first approved therapy for H3K27M-mutant diffuse midline glioma. Management says Riga has 25+ years of industry experience and led over $2 billion in business development deals in the past five years.

Positive

• Named experienced dealmaker with >25 years in pharma
• Directed the Chimerix sale to Jazz, strengthening M&A bench
• Helped secure U.S. approval and launch of Modeyso for H3K27M-mutant diffuse midline glioma
• Led >$2 billion in business development deals in the past five years

Negative

• None.

Argus Jan 9 session

+0.55% close to close Open Argus

Details

News Market Reaction – JAZZ

On Jan 9, the first trading day after this news, JAZZ closed 0.55% above the previous close.

Data tracked by StockTitan Argus for the Jan 9 session.

Market Context

This announcement highlights a leadership appointment aimed at strengthening Jazz’s corporate develo...

Analysis

This announcement highlights a leadership appointment aimed at strengthening Jazz’s corporate development and partnership execution. It follows a series of recent clinical advances and data updates in oncology, sleep, and epilepsy. When evaluating such changes, investors often focus on the appointee’s transaction track record, alignment with existing portfolio priorities, and integration with ongoing trial and commercialization plans. Upcoming data events, regulatory milestones, and capital allocation disclosures remain key metrics to watch for assessing longer-term impact.

Key Figures

Industry experience: Over 25 years Patient population: Approximately 2,000 Deal value: Over $2 billion

Industry experience

Over 25 years

Thomas Riga’s commercial and operational experience in pharmaceuticals

Patient population

Approximately 2,000

Children and young adults in U.S. annually with H3K27M-mutant diffuse midline glioma

Deal value

Over $2 billion

Business development transactions led by Riga in past five years

Historical Context

5 past events · Latest: Jan 06

5 events

1. Jan 06

   Phase 3 results

   24h Move

   -4.2%

   Positive Phase 3 HERIZON-GEA-01 Ziihera survival and PFS results.

2. Dec 17

   Investor events update

   24h Move

   -2.8%

   Announcement of upcoming webcasts and JPM healthcare conference presentation.

3. Dec 09

   Sleep data update

   24h Move

   -4.0%

   New Xywav data and real-world sleep outcomes at major psychiatry meetings.

4. Dec 05

   Epilepsy data update

   24h Move

   +2.0%

   Extensive Epidiolex data and real-world evidence at epilepsy society meeting.

5. Dec 02

   Pivotal trial preview

   24h Move

   +0.2%

   Announcement of pivotal Phase 3 Ziihera results to be presented at ASCO GI.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

H3K27M-mutant, diffuse midline glioma

2 terms

H3K27M-mutant medical

"first approved therapy for H3K27M-mutant diffuse midline glioma affecting approximately..."

A H3K27M‑mutant is a specific, single‑amino‑acid change in the histone H3 protein (lysine at position 27 replaced by methionine) that alters how genes are turned on and off in certain aggressive brain tumors. For investors, it matters because this clear biological marker can determine patient diagnosis and prognosis, guide clinical trial eligibility, and create opportunities for targeted drugs or diagnostics, which can materially affect the commercial value of therapies and related companies.

diffuse midline glioma medical

"first approved therapy for H3K27M-mutant diffuse midline glioma affecting approximately..."

An aggressive, hard-to-treat brain tumor that grows in the central parts of the brain or spinal cord, often disrupting critical functions like movement and speech much like a weed taking root in the engine of a machine. It matters to investors because its severity and limited treatment options create high unmet medical need, which can drive the value of research programs, regulatory incentives, drug pricing and the commercial prospects of therapies in development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions

DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026.

Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory environment leading to successful U.S. approval and launch of the first approved therapy for H3K27M-mutant diffuse midline glioma affecting approximately 2,000 children and young adults in the U.S. annually. He brings more than 25 years of experience in the pharmaceutical industry leading sales and marketing, business development, operations, and has held multiple C-suite positions across various organizations. In his role as chief business officer, he will lead execution of corporate development initiatives and drive strategic partnerships for the company.

"Tom is an exceptional leader with more than 25 years in the pharmaceutical industry and a proven record of driving strategic transactions," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. "He combines a passion for patients with deep commercial, operational, and corporate development expertise, having led over $2 billion in business development deals in the past five years. Tom played a pivotal role in the approval and launch of Modeyso™ (dordaviprone), the first treatment for an ultra-rare, aggressive brain tumor affecting primarily children and young adults. His commitment to patients who previously had no options is truly inspiring. I look forward to working with Tom in this new capacity to strengthen our corporate development capabilities and continue bringing innovative medicines to Jazz's portfolio that transform lives."

"I am honored to take on this new role of chief business officer at Jazz," said Mr. Riga. "I've been impressed by the strength and vision of Jazz's leadership team and look forward to advancing the company through innovative strategic transactions that leverage the existing expertise and capabilities of the company. Together, we will continue to build on our proven corporate development engine to deliver shareholder value and, most importantly, make a meaningful impact for patients with unmet medical need."

About Jazz Pharmaceuticals 
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:
Jazz Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

Jazz Investor Contact:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com 
Ireland +353 1 634 3211
U.S. +1 650 496 2717

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-appoints-thomas-riga-as-chief-business-officer-302656729.html

SOURCE Jazz Pharmaceuticals plc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did Jazz Pharmaceuticals appoint Thomas Riga as Chief Business Officer (JAZZ)?

Thomas Riga was appointed Chief Business Officer effective January 1, 2026.

What roles did Thomas Riga hold before joining Jazz Pharmaceuticals (JAZZ)?

He served as chief operating and commercial officer at Chimerix and held multiple C-suite roles across the biopharma industry.

How did Mr. Riga join Jazz Pharmaceuticals (JAZZ)?

He joined Jazz in April 2025 via Jazz's acquisition of Chimerix, where he had been chief operating and commercial officer.

What commercial and regulatory achievements is Thomas Riga credited with at Chimerix?

He led the transaction selling Chimerix to Jazz and helped navigate approval and launch of Modeyso (dordaviprone) for H3K27M-mutant diffuse midline glioma.

What business-development experience does Thomas Riga bring to Jazz (JAZZ)?

Management states he has led over $2 billion in business development deals in the past five years.